Related references
Note: Only part of the references are listed.
Article
Infectious Diseases
Hiroaki Sasaki et al.
Summary: This study evaluated the antibody titers among COVID-19 patients treated with REGN-COV. The results showed an elevation of IgG(SP) after REGN-COV administration, which was correlated with the reciprocal of ideal body weight.
Article
Multidisciplinary Sciences
Sarah Adamo et al.
Summary: Researchers used spectral flow cytometry combined with cellular indexing of transcriptomes and T cell receptor sequencing to longitudinally characterize individual SARS-CoV-2-specific CD8(+) T cells from patients with COVID-19, identifying a distinct signature marking long-lived memory CD8(+) T cells. The study found that SARS-CoV-2-specific memory CD8(+) T cells persisting 1 year after acute infection express specific markers and exhibit characteristics resembling effector memory T cells, and that certain transcriptional signatures and signaling pathways are associated with the fate of individual clones of these cells.
Review
Immunology
Paul Moss
Summary: T cell immunity plays a central role in controlling SARS-CoV-2 infection, with early responses correlating with protection. T cell memory provides broad recognition of viral proteins, limiting the impact of viral variants and offering protection against severe disease. Current COVID-19 vaccines elicit robust T cell responses, contributing to the prevention of hospitalization or death. Therefore, the importance of T cell immunity may have been underestimated.
Article
Medicine, Research & Experimental
Lichen Jing et al.
Summary: SARS-CoV-2 elicits a strong T cell response, with CD8 and CD4 T cells from convalescent individuals recognizing infected cells and inactivated whole viral antigen respectively. CD8 T cells exhibit low specificity, while CD4 T cells show higher breadth. Additionally, some CD4 T cell lines enriched using SARS-CoV-2 can cross-recognize seasonal coronavirus antigens.
Review
Virology
Sahar Sotoodeh Ghorbani et al.
Summary: Studies have shown cases of COVID-19 patients testing positive for the virus again after recovery, with higher reinfection rates in males and more frequent recurrence in females. Uncertainty regarding long-term immunity after SARS-Cov-2 infection indicates the possibility of reinfection and recurrence post-recovery. Efforts like mass vaccination and proper disease management can help control the frequent occurrence of the disease.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Review
Multidisciplinary Sciences
Miriam Merad et al.
Summary: Considerable research effort has been focused on deciphering the immune response to SARS-CoV-2 infections and understanding the pathophysiology of COVID-19, including Long Covid syndrome. The hope is that knowledge gained from this research will be applied to studies of inflammatory processes in critical and chronic illnesses in the future.
Article
Immunology
Maria De Santis et al.
Summary: The efficacy and safety of the Moderna-1273 mRNA vaccine were evaluated in patients with immune-mediated diseases under different treatments. The study found that mycophenolate treatment may impair vaccine immunogenicity, and higher doses were associated with a lower humoral response. These findings suggest the need to consider the effects of different immunotherapies when selecting a vaccination regimen.
Letter
Infectious Diseases
Kim Blom et al.
LANCET INFECTIOUS DISEASES
(2022)
Article
Cell Biology
Robert J. Benschop et al.
Summary: This study evaluated the endogenous antibody response to COVID-19 vaccination in participants who had previously received a COVID-19 monoclonal antibody for prevention. The findings indicate that all participants, regardless of age, risk category, or vaccine type, mounted a strong immune response to full COVID-19 vaccination. The study suggests that the benefits of receiving COVID-19 vaccination outweigh any minimal effect on the endogenous immune response due to prior monoclonal antibody treatment.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Microbiology
Carmela De Marco et al.
Summary: This study reports on the surveillance of SARS-CoV-2 in Southern Italy from March 2021 to February 2022. The study identified the circulating variants in the region and their dynamics over time, with Delta and Omicron becoming the dominant variants. The study also analyzed the distribution of these variants across Europe and different regions of Italy and predicted the effects of specific mutations on the host immune response.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Critical Care Medicine
Hugh Montgomery et al.
Summary: This study evaluated the safety and efficacy of tixagevimab-cilgavimab in preventing severe COVID-19 or death in non-hospitalized adults. The results showed that a single dose of tixagevimab-cilgavimab significantly reduced the risk of progression to severe COVID-19 or death, with favorable safety.
LANCET RESPIRATORY MEDICINE
(2022)
Article
Immunology
Sebastian Havervall et al.
Summary: This study investigated the long-term impact of prior SARS-CoV-2 infection on immune responses after COVID-19 vaccination. The results showed that prior SARS-CoV-2 infection substantially enhanced T-cell responses, anti-spike IgG responses, and neutralising antibodies in vaccinated individuals. These findings suggest that prior infection should be considered when planning future COVID-19 vaccine programs.
CLINICAL & TRANSLATIONAL IMMUNOLOGY
(2022)
Article
Immunology
Annika Nelde et al.
Summary: SARS-CoV-2-specific T cell epitopes were identified in convalescent and unexposed individuals, showing cross-reactivity with common cold coronaviruses. The diversity of SARS-CoV-2 T cell responses may be associated with mild symptoms of COVID-19.
Review
Biochemistry & Molecular Biology
Alessandro Sette et al.
Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.
Article
Medicine, General & Internal
D. M. Weinreich et al.
Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Gastroenterology & Hepatology
Saifu Yin et al.
Article
Medicine, General & Internal
Anil Gupta et al.
Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Adam K. Wheatley et al.
Summary: The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection and vaccine development. Antibody, B cell, and T cell responses decline over the first 4 months post-infection, while S-specific IgG(+) memory B cells consistently accumulate. The study suggests that natural infection may only provide transient protection at a population level, highlighting the need for more immunogenic and durable vaccines.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
Lin Zhang et al.
Summary: In patients with mild or moderate COVID-19 treated with monoclonal antibodies, a wide range of antigenic responses to SARS-CoV-2 were developed. Small reductions in titers and neutralizing activity were observed, potentially due to decreased viral load following antibody treatment, suggesting minimal impact on the endogenous immune response.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Ricardo da Silva Antunes et al.
Summary: The study found that SARS-CoV-2 seronegative healthcare workers had higher CD4(+) T-cell responses against common cold coronaviruses, possibly due to higher occupational exposure. Additionally, exposure to SARS-CoV-2 may decrease T-cell reactivity against common cold coronaviruses, as observed in independent cohorts from Miami and San Diego.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
Carolina Lucas et al.
Summary: Recent studies have shown that COVID-19 mortality is not primarily correlated with antiviral antibody levels, but more with the slower kinetics of antibody production.
Review
Biochemistry & Molecular Biology
Davide Corti et al.
Summary: Monoclonal antibodies have revolutionized the treatment of several human diseases, including cancer, autoimmunity, and infectious diseases. Lessons learned from the COVID-19 pandemic have paved the way for the development of more monoclonal antibody-based therapeutics.
Review
Microbiology
Alba Grifoni et al.
Summary: This review summarizes recent studies on SARS-CoV-2 T cell epitopes, highlighting the significant correlation between epitope number and antigen size. It also presents an analysis of 1,400 different reported SARS-CoV-2 epitopes and identifies discrete immunodominant regions of the virus and more prevalently recognized epitopes.
CELL HOST & MICROBE
(2021)
Article
Multidisciplinary Sciences
Florian A. Lempp et al.
Summary: The study reveals that C-type lectin receptors and other factors can serve as attachment receptors for SARS-CoV-2 infection, enhancing ACE2-mediated infection and modulating the neutralizing activity of antibodies.
Article
Multidisciplinary Sciences
Valerie Oberhardt et al.
Summary: After vaccination, CD8(+) T cells become important effector cells in providing early protection, being effectively mobilized one week after primary vaccination and maintaining stability after booster vaccination. Compared with natural infection, vaccine-induced CD8(+) T cells exhibit similar functional capacities but with a different subset distribution.
Article
Medicine, General & Internal
M. Dougan et al.
Summary: In this phase 3 trial, the combination of bamlanivimab plus etesevimab was found to reduce the incidence of Covid-19-related hospitalization and death among high-risk ambulatory patients compared to placebo, and also accelerated the decline in SARS-CoV-2 viral load.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Jae Hyung Jung et al.
Summary: The study reveals that memory T cell responses can be detected in convalescent COVID-19 patients up to 317 days post-symptom onset, indicating potential long-lasting immunity, especially with the presence of stem cell-like memory T cells.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
Daryl Geers et al.
Summary: This study suggests that some variants might partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 vaccination, but the S-specific CD4(+) T-cell activation is not affected by the mutations in the B.1.1.7 and B.1.351 variants.
SCIENCE IMMUNOLOGY
(2021)
Article
Immunology
Megan E. Schmidt et al.
MUCOSAL IMMUNOLOGY
(2020)
Article
Biochemistry & Molecular Biology
Takuya Sekine et al.
Article
Multidisciplinary Sciences
Stylianos Bournazos et al.
Article
Multidisciplinary Sciences
Till Schoofs et al.
Article
Virology
Seyhan Boyoglu-Barnum et al.
JOURNAL OF VIROLOGY
(2014)
Article
Virology
J. Pablo Jaworski et al.
JOURNAL OF VIROLOGY
(2013)
Article
Multidisciplinary Sciences
Dan H. Barouch et al.
Article
Biochemistry & Molecular Biology
Cherie T. Ng et al.
Article
Virology
NL Haigwood et al.
JOURNAL OF VIROLOGY
(2004)